tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.
Company profile
Ticker
TFFP
Exchange
Website
CEO
Glenn R. Mattes
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
TFF Pharmaceuticals Australia Pty Ltd ...
IRS number
824344737
TFFP stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-1
IPO registration
18 Apr 24
S-1
IPO registration
8 Apr 24
D
$1.18 mm in options / securities to be acquired, 2 investors
2 Apr 24
8-K
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Regulation FD Disclosure
27 Mar 24
8-K
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22 Mar 24
Transcripts
TFFP
Earnings call transcript
2023 Q3
14 Nov 23
TFFP
Earnings call transcript
2023 Q2
15 Aug 23
TFFP
Earnings call transcript
2022 Q3
15 Nov 22
TFFP
Earnings call transcript
2022 Q2
12 Aug 22
TFFP
Earnings call transcript
2022 Q1
12 May 22
TFFP
Earnings call transcript
2021 Q4
25 Mar 22
TFFP
Earnings call transcript
2021 Q3
16 Nov 21
TFFP
Earnings call transcript
2021 Q2
13 Aug 21
TFFP
Earnings call transcript
2021 Q1
14 May 21
TFFP
Earnings call transcript
2020 Q4
11 Mar 21
Latest ownership filings
4
THOMAS BRAXTON KING
22 Apr 24
4
Michael A Patane
22 Apr 24
4
Catherine Chai-zon Lee
22 Apr 24
4
ROBERT S MILLS
22 Apr 24
4
Brandi Roberts
22 Apr 24
4
KIRK ALLEN COLEMAN
22 Apr 24
4
Zamaneh Mikhak
22 Apr 24
4
STEPHEN ROCAMBOLI
22 Apr 24
4
Harlan F Weisman
22 Apr 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.73 mm | 9.73 mm | 9.73 mm | 9.73 mm | 9.73 mm | 9.73 mm |
Cash burn (monthly) | (no burn) | 285.11 k | 1.47 mm | 1.99 mm | 1.00 mm | 1.63 mm |
Cash used (since last report) | n/a | 1.96 mm | 10.11 mm | 13.67 mm | 6.86 mm | 11.16 mm |
Cash remaining | n/a | 7.77 mm | -384.75 k | -3.94 mm | 2.86 mm | -1.44 mm |
Runway (months of cash) | n/a | 27.3 | -0.3 | -2.0 | 2.9 | -0.9 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 2 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 2.53 bn |
Total shares | 9.37 mm |
Total puts | 0.00 |
Total calls | 34.40 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lung Therapeutics | 2.95 mm | $42.24 mm |
AIGH Capital Management | 1.56 mm | $731.10 mm |
Carlson Capital L P | 1.28 mm | $601.60 mm |
DRW Securities | 1.00 mm | $470.00 k |
Vanguard | 853.66 k | $401.22 mm |
Worth Venture Partners | 389.11 k | $182.88 mm |
BLK Blackrock | 213.90 k | $100.53 mm |
Geode Capital Management | 187.88 k | $88.30 mm |
Gagnon Securities | 161.07 k | $75.70 mm |
Sigma Planning | 145.05 k | $68.17 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | King Thomas Braxton | RSU Common stock | Grant | Acquire A | No | No | 0 | 3,110 | 0.00 | 3,110 |
18 Apr 24 | Michael A Patane | RSU Common stock | Grant | Acquire A | No | No | 0 | 3,556 | 0.00 | 3,556 |
18 Apr 24 | Catherine Chai-zon Lee | RSU Common stock | Grant | Acquire A | No | No | 0 | 3,556 | 0.00 | 3,556 |
18 Apr 24 | Robert S Mills | RSU Common stock | Grant | Acquire A | No | No | 0 | 4,667 | 0.00 | 4,667 |
18 Apr 24 | Roberts Brandi | RSU Common stock | Grant | Acquire A | No | No | 0 | 5,333 | 0.00 | 5,333 |
News
TFF Pharmaceuticals Announces Additional Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
15 Apr 24
TFF Pharmaceuticals Q4 EPS $(2.01) Beats $(2.12) Estimate, Sales $114.33K Beat $100.00K Estimate
28 Mar 24
Roth MKM Maintains Buy on TFF Pharmaceuticals, Lowers Price Target to $44
28 Mar 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Mar 24
TFF Pharmaceuticals Announces Oral Presentation Of Interim Data From The Phase 2 Study Of Tacrolimus Inhalation Powder For The Prevention Of Lung Transplant Rejection At The 44th Annual ISHLT 2024 Meeting
25 Mar 24
Press releases
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
27 Mar 24
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
25 Mar 24
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22 Mar 24
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
20 Mar 24
TFF Pharmaceuticals Announces Update on Clinical Programs
20 Mar 24